SG11202104205XA - Engineered primate cystine/cysteine degrading enzymes for therapeutic uses - Google Patents
Engineered primate cystine/cysteine degrading enzymes for therapeutic usesInfo
- Publication number
- SG11202104205XA SG11202104205XA SG11202104205XA SG11202104205XA SG11202104205XA SG 11202104205X A SG11202104205X A SG 11202104205XA SG 11202104205X A SG11202104205X A SG 11202104205XA SG 11202104205X A SG11202104205X A SG 11202104205XA SG 11202104205X A SG11202104205X A SG 11202104205XA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic uses
- degrading enzymes
- cystine
- cysteine degrading
- engineered primate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y404/00—Carbon-sulfur lyases (4.4)
- C12Y404/01—Carbon-sulfur lyases (4.4.1)
- C12Y404/01001—Cystathionine gamma-lyase (4.4.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/225—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862751197P | 2018-10-26 | 2018-10-26 | |
PCT/US2019/058021 WO2020086937A1 (en) | 2018-10-26 | 2019-10-25 | Engineered primate cystine/cysteine degrading enzymes for therapeutic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104205XA true SG11202104205XA (en) | 2021-05-28 |
Family
ID=70331739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104205XA SG11202104205XA (en) | 2018-10-26 | 2019-10-25 | Engineered primate cystine/cysteine degrading enzymes for therapeutic uses |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210380962A1 (en) |
EP (1) | EP3870081A4 (en) |
JP (1) | JP2022505689A (en) |
KR (1) | KR20210084539A (en) |
CN (1) | CN113260324A (en) |
AR (1) | AR116866A1 (en) |
AU (1) | AU2019363606A1 (en) |
BR (1) | BR112021007687A2 (en) |
CA (1) | CA3117046A1 (en) |
CO (1) | CO2021006432A2 (en) |
IL (1) | IL282626A (en) |
MX (1) | MX2021004754A (en) |
SG (1) | SG11202104205XA (en) |
TW (1) | TW202029967A (en) |
WO (1) | WO2020086937A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060275279A1 (en) * | 2005-06-06 | 2006-12-07 | Rozzell J D | Methods for dissolving cystine stones and reducing cystine in urine |
AU2011212885B2 (en) * | 2010-02-04 | 2015-10-01 | Aemase, Inc. | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof |
AU2014312168B2 (en) * | 2013-08-29 | 2020-08-06 | Board Of Regents, The University Of Texas System | Engineered primate cystine/cysteine degrading enzymes as antineogenic agents |
CA2922550C (en) * | 2013-08-29 | 2022-12-06 | Board Of Regents, The University Of Texas System | Engineered primate l-methioninase for therapeutic purposes |
EP3187190A1 (en) * | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
WO2018209211A1 (en) * | 2017-05-12 | 2018-11-15 | Board Of Regents, The University Of Texas System | Engineered primate cystine/cysteine degrading enzymes for therapeutic uses |
-
2019
- 2019-10-25 MX MX2021004754A patent/MX2021004754A/en unknown
- 2019-10-25 TW TW108138620A patent/TW202029967A/en unknown
- 2019-10-25 WO PCT/US2019/058021 patent/WO2020086937A1/en active Application Filing
- 2019-10-25 AU AU2019363606A patent/AU2019363606A1/en not_active Abandoned
- 2019-10-25 CA CA3117046A patent/CA3117046A1/en active Pending
- 2019-10-25 US US17/288,151 patent/US20210380962A1/en active Pending
- 2019-10-25 SG SG11202104205XA patent/SG11202104205XA/en unknown
- 2019-10-25 BR BR112021007687-5A patent/BR112021007687A2/en unknown
- 2019-10-25 JP JP2021522334A patent/JP2022505689A/en active Pending
- 2019-10-25 EP EP19874951.7A patent/EP3870081A4/en active Pending
- 2019-10-25 CN CN201980079530.0A patent/CN113260324A/en active Pending
- 2019-10-25 KR KR1020217015692A patent/KR20210084539A/en unknown
- 2019-10-25 AR ARP190103101A patent/AR116866A1/en unknown
-
2021
- 2021-04-25 IL IL282626A patent/IL282626A/en unknown
- 2021-05-18 CO CONC2021/0006432A patent/CO2021006432A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3870081A4 (en) | 2023-01-18 |
CA3117046A1 (en) | 2020-04-30 |
TW202029967A (en) | 2020-08-16 |
AR116866A1 (en) | 2021-06-23 |
WO2020086937A1 (en) | 2020-04-30 |
IL282626A (en) | 2021-06-30 |
BR112021007687A2 (en) | 2021-08-10 |
MX2021004754A (en) | 2021-06-08 |
US20210380962A1 (en) | 2021-12-09 |
JP2022505689A (en) | 2022-01-14 |
CO2021006432A2 (en) | 2021-06-10 |
EP3870081A1 (en) | 2021-09-01 |
KR20210084539A (en) | 2021-07-07 |
CN113260324A (en) | 2021-08-13 |
AU2019363606A1 (en) | 2021-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL244263B (en) | Engineered primate cystine/cysteine degrading enzymes as antineogenic agents | |
IL282092B (en) | Engineered enzymes | |
EP3490987A4 (en) | Novel therapeutic agents for the treatment of hbv infection | |
EP3576765A4 (en) | Targeted engineered interferon and uses thereof | |
EP4073232A4 (en) | Organoid cultures | |
IL275482A (en) | Esketamine for the treatment of depression | |
IL261856B (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
EP3705545A4 (en) | Surface treatment composition | |
AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
IL279880A (en) | Engineered phosphopentomutase variant enzymes | |
EP3445179A4 (en) | Cannabis-enriched enzymatically treated therapeutic composition | |
EP3481425A4 (en) | Human-enzyme mediated depletion of cystine for treating patients with cystinuria | |
IL285634A (en) | Novel uses of botulinum neurotoxin for the treatment of tremor | |
IL288937A (en) | Improved treatment using eyp001 | |
GEP201706673B (en) | Compositions containing chondroitin sulphate, proteolytic enzymes and sulphydryl compounds for improving the bioavailability of chondroitin sulphate | |
GB201916237D0 (en) | Novel treatment | |
EP3880885A4 (en) | Surface treatment composition | |
GB202007431D0 (en) | Cysteine protease | |
IL282626A (en) | Engineered primate cystine/cysteine degrading enzymes for therapeutic uses | |
EP3722867A4 (en) | Soft contact lens treatment solution | |
EP3679046A4 (en) | Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof | |
EP3684309A4 (en) | Devices and methods for reducing cystine crystalsin vivo | |
EP3573609A4 (en) | Use of senicapoc for treatment of stroke | |
IL286000A (en) | Esketamine for the treatment of depression | |
EP3576750A4 (en) | Idoxuridine and its analogs as neuroprotectans for the treatment of parkinsonism |